CIGB-552: A Peptide Candidate for Cancer Therapy

A review paper from the Centro de Ingeniería Genética y Biotecnología presents experimental data on the antitumor peptide CIGB-552. The data covers its mechanism of action, targeting the COMMD1 protein and inhibiting NF-kB signaling, and its therapeutic potential validated in vitro and in vivo. The peptide is currently in phase I clinical trials as an antineoplastic drug.

Use Cases

• Analyzing peptide-based cancer therapy mechanisms based on the described targeting of COMMD1 and RelA degradation.
• Training models to predict drug efficacy based on in vitro and in vivo validation data mentioned in the review.
• Studying the therapeutic potential of peptides for inflammatory and metabolic conditions based on the described possible applications.

Strengths

• Data is derived from a published scientific review, providing a synthesized expert perspective.
• The description details a specific molecular mechanism (COMMD1 targeting, RelA degradation) and validation across multiple models (cell lines, mouse models, dogs).
• The dataset is associated with an ongoing phase I clinical trial, indicating translational relevance.

Limitations

• The underlying dataset structure, including columns and rows, is unknown.
• The data is presented as a review article, not as structured, machine-readable data files.
• The last update date is unknown; freshness unverified.

Provenance

Source

Centro de Ingeniería Genética y Biotecnología

Collection Method

A review paper synthesizing experimental data.